Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Praluent Market Growth From $ Billion In 2026 To $ Billion By 2030 At A CAGR Of %
Expansion in the historical timeframe can be explained by factors such as the increasing occurrence of high cholesterol, the shortcomings of treatments relying exclusively on statins, broader screening programs for cardiovascular risk, development of biologic therapies for heart conditions, and a rise in specialized cardiology services.
The expansion projected for the forecast period stems from a heightened emphasis on aggressive lipid-lowering approaches, broader use in secondary prevention, the growth of value-based cardiovascular care, stronger payer endorsement for PCSK9 inhibitors, and greater public awareness around reducing cardiovascular risk. Key developments shaping this period involve the growing incorporation of PCSK9 inhibitors into lipid management, their increasing application among high-risk cardiovascular patients, more frequent integration with statin combination therapy, the extension of preventive cardiology initiatives, and a reinforced commitment to achieving long-term LDL control.
Download A Free Sample Report For Comprehensive Market Insights:
Praluent Market Demand Drivers Creating New Revenue Opportunities
The anticipated growth of the praluent market will likely be driven by the rising prevalence of obesity. This condition involves the excessive accumulation of body fat that endangers health, generally identified when an individual has a Body Mass Index (BMI) of 30 or more. Its increasing frequency stems largely from changes in global dietary patterns and food systems, marked by a higher intake of ultra-processed foods, inactive ways of living, and economic conditions that make unhealthy food options more accessible. As a PCSK9 inhibitor, praluent addresses obesity by boosting the liver’s capacity to clear LDL cholesterol from circulation, lowering LDL cholesterol levels in individuals with obesity-related dyslipidemia, and consequently enhancing heart health while mitigating complications linked to obesity. To illustrate, a May 2024 report from the Office for Health Improvement and Disparities—a UK government body overseeing public health strategies—indicated that during 2022–2023, 64.0% of adults aged 18 and over in England were overweight or had obesity, with 26.2% specifically living with obesity (BMI = 30 kg/m²). As a result, the upward trend in obesity will propel the expansion of the praluent market.
The escalating use of personalized medicine is set to fuel growth in the Praluent market moving ahead. In this approach, clinicians customize treatments based on an individual’s distinct biological traits to achieve better health outcomes. Its growing application is fueled by a preference among healthcare providers for therapies that correspond with genetic and biomarker signatures, enabling greater treatment accuracy. Since its targeted action as a PCSK9 inhibitor enables clinicians to customize LDL-cholesterol reduction according to each patient’s cardiovascular risk profile, Praluent is well-suited to support the rise of personalized medicine. Evidence for this comes from BioSpace, Inc., a U.S. life science news platform, which reported in February 2025 that the FDA authorized 16 new personalized therapies for rare disease patients in 2023, a jump from six the prior year. Consequently, the expanding uptake of personalized medicine is anticipated to accelerate the Praluent market’s growth.
Praluent Market Segment Analysis And Revenue Opportunities
The praluent market covered in this report is segmented –
1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD)
2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies
3) By End-User: Ambulatory Care, Home Care
Praluent Market Trends Driving Strategic Industry Expansion
Major players within the praluent market are prioritizing the creation of cutting-edge solutions, including low-density lipoprotein cholesterol (LDL-C) lowering therapies, to address the growing need for advanced treatments for cardiovascular risk reduction. These LDL-C–lowering therapies represent specialized medical approaches precisely engineered to drastically decrease levels of “bad cholesterol,” delivering more accurate, targeted, and sustained control over lipids than what is achievable through standard statins or lifestyle adjustments alone. A notable example occurred in March 2024, when Regeneron Pharmaceuticals Inc., a biotechnology firm headquartered in the United States, secured an extended approval from the U.S. Food and Drug Administration (FDA) for Praluent (alirocumab) injection, an advanced biologic therapy designed for LDL-C reduction. This renewed clearance permits its application as a supplementary treatment alongside dietary measures and existing lipid-lowering regimens for pediatric individuals aged 8 and older who are affected by heterozygous familial hypercholesterolemia (HeFH). Praluent acts as a PCSK9 inhibitor monoclonal antibody that enhances LDL receptor accessibility, leading to pronounced and prolonged decreases in LDL-C levels. The therapy is characterized by its strong effectiveness, a reassuring safety profile, and a reduced dosing frequency when compared with numerous conventional lipid-lowering alternatives. By broadening access to children with genetic forms of high cholesterol, this product aids in managing early-emerging cardiovascular hazards and promotes sustained heart health management over the long term.
Praluent Market Leading Players Shaping Industry Direction
Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.
Access The Complete Praluent Market Report:
Praluent Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model